ReviewBiochimica et biophysica acta
High-mobility group box 1 and cancer.
Review in Biochimica et biophysica acta. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02056782 (A Pilot Study to Evaluate the Safety and Preliminary Evidence of an Effect of ODSH), which is not on this map. Cited by 291 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Pilot Study to Evaluate the Safety and Preliminary Evidence of an Effect of ODSH (2 O, 3-O Desulfated Heparin) in Accelerating Platelet Recovery in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia
Who cites it
291 citing papers in PubMed, 2 syntheses or guidelines pooled it, 508 citations in OpenAlex.
- HMGB1: an overview of its versatile roles in the pathogenesis of colorectal cancer.Cellular oncology (Dordrecht, Netherlands) · 2020Pooled it
- HMGB1 overexpression as a prognostic factor for survival in cancer: a meta-analysis and systematic review.Oncotarget · 2016Pooled it
- Autophagy-associated HMGB-1 as a novel potential circulating non-invasive diagnostic marker for detection of Urothelial Carcinoma of Bladder.Molecular and cellular biochemistry · 2022Trial
- Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination.Nature medicine · 2019Trial
- Effects of Dexmedetomidine Infusion on Inflammatory Responses and Injury of Lung Tidal Volume Changes during One-Lung Ventilation in Thoracoscopic Surgery: A Randomized Controlled Trial.Mediators of inflammation · 2018Trial
- Inflammatory Response After Laparoscopic Versus Open Resection of Colorectal Liver Metastases: Data From the Oslo-CoMet Trial.Medicine · 2015Trial
- HMGB1 directly activates BAP1 transcription to sustain tumor growth in mesothelioma.Cell death and differentiation · 2026Article
- Potential for anti‑angiogenic therapy targeting the receptor for advanced glycation end products/VEGF axis in ulcerative colitis (Review).Molecular medicine reports · 2026Review
- Baseline Extracellular HMGB-1 Levels Associated with Induction Chemotherapy Response in Adult Acute Myeloid Leukemia.F1000Research · 2026Article
- Targeting MD2 in prostate cancer bone metastasis: Mechanistic insights and therapeutic potential.Oncoscience · 2026Article
- Characterization of the Intact Proteomic Profile of Senescent-Associated Secretory Phenotype by Top-Down Mass Spectrometry.Analytical chemistry · 2025Article
- The HMGB1-RAGE Axis Drives the Proneural-to-Mesenchymal Transition and Aggressiveness in Glioblastoma.International journal of molecular sciences · 2025Article
- Article
- The role of Box A of HMGB1 in producing γH2AX associated DNA breaks in lung cancer.Scientific reports · 2025Article
- Mechanism of action of HMGB1 in urologic malignancies.Frontiers in oncology · 2025Review
- HMGB1 promotes chemoresistance in small cell lung cancer by inducing PARP1-related nucleophagy.Journal of advanced research · 2024Article
- A pan-cancer analysis of the oncogenic function of HMGB1 in human tumors.Biochemistry and biophysics reports · 2024Article
- MicroRNA-mediated autophagy and drug resistance in cancer: mechanisms and therapeutic strategies.Discover oncology · 2024Review
- The crosstalk between immune cells and tumor pyroptosis: advancing cancer immunotherapy strategies.Journal of experimental & clinical cancer research : CR · 2024Review
- Andrographolide anti-proliferation and metastasis of hepatocellular carcinoma through LncRNA MIR22HG regulation.Journal of natural medicines · 2024Article
231 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
High-mobility group box 1 protein (HMGB1), a chromatin associated nuclear protein and extracellular damage associated molecular pattern molecule (DAMP), is an evolutionarily ancient and critical regulator of cell death and survival. Overexpression of HMGB1 is associated with each of the hallmarks of cancer including unlimited replicative potential, ability to develop blood vessels (angiogenesis), evasion of programmed cell death (apoptosis), self-sufficiency in growth signals, insensitivity to inhibitors of growth, inflammation, tissue invasion and metastasis. Our studies and those of our colleagues suggest that HMGB1 is central to cancer (abnormal wound healing) and many of the findings in normal wound healing as well. Here, we focus on the role of HMGB1 in cancer, the mechanisms by which it contributes to carcinogenesis, and therapeutic strategies based on targeting HMGB1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.